The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

##STR00001##

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

##STR00001##

The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia

(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

Provided is a compound of Formula 1: ##STR00001##
where X is O or S; Ar.sub.1 is an aryl having 6 to 20 carbon atoms substituted with at least one functional group selected from the group consisting of cyano, pyridinyl, benzimidazolyl and diphenylphosphine oxide, or a substituted or unsubstituted heteroaryl having 3 to 20 carbon atoms containing at least one N; and Ar.sub.2 is a functional group of Formula 2 below, with the proviso that Ar.sub.1 and Ar.sub.2 are different from each other, ##STR00002##
where Ar.sub.3 is an aryl having 6 to 20 carbon atoms, and m is an integer of 0 to 2, and an organic light emitting device comprising the same.

Provided is a compound of Formula 1: ##STR00001##
where X is O or S; Ar.sub.1 is an aryl having 6 to 20 carbon atoms substituted with at least one functional group selected from the group consisting of cyano, pyridinyl, benzimidazolyl and diphenylphosphine oxide, or a substituted or unsubstituted heteroaryl having 3 to 20 carbon atoms containing at least one N; and Ar.sub.2 is a functional group of Formula 2 below, with the proviso that Ar.sub.1 and Ar.sub.2 are different from each other, ##STR00002##
where Ar.sub.3 is an aryl having 6 to 20 carbon atoms, and m is an integer of 0 to 2, and an organic light emitting device comprising the same.

In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an organic solvent and an acid catalyst to obtain a compound of formula IV, and due to such method, provided are a novel photoreactive compound and a method for producing same that can be used for nucleic acid photoreaction technology.

The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV.

The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV.